Answers are grounded in this paper and cite their sources.
Data on real-world prevalence and outcomes in patients diagnosed with pathogenic germline variants in BRCA1 or BRCA2 (gBRCAm) breast cancer is sparse.
No takes yet. Share an insight, caveat, or question.
Karihtala et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: